AssetMark Inc
COGT icon

AssetMark Inc’s Cogent Biosciences COGT Stock Holding History

AssetMark Inc’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$707K Sell
18,279
-708
-4% -$24.8K ﹤0.01% 1153
2026
Q1 		$731K Buy
+18,987
New +$701K ﹤0.01% 1091

Other funds holding COGT

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $2B AUM 42.86% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

AssetMark Inc's COGT Position: Q2 2026 in Review

AssetMark Inc reduced its Cogent Biosciences (COGT) stake by 3.7% in Q2 2026, selling an estimated $24.8K and leaving 18,279 shares worth $707K. The position accounts for ﹤0.01% of the portfolio, ranked #1153.

AssetMark Inc first reported a position in COGT in Q1 2026 and has held it in 2 quarters since. The position peaked at $731K in Q1 2026. 47 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • AssetMark Inc held 18,279 shares of Cogent Biosciences worth $707K as of Q2 2026.
  • AssetMark Inc sold 708 Cogent Biosciences shares in Q2 2026, an estimated $24.8K.
  • Cogent Biosciences made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1153 holding.
  • AssetMark Inc first reported a position in Cogent Biosciences in Q1 2026 and has held it in 2 quarters since.
  • AssetMark Inc's Cogent Biosciences position peaked at $731K in Q1 2026.
  • 47 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.